Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

What if infections of respiratory syncytial virus, known as R.S.V., peak at unusual levels, as they did in the 2022-23 season? What if the new strain of mpox, which is especially virulent ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

2024 — This multi-state study is a real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine. VISION ... Nov. 7, 2024 — Increased ...